Australia markets closed

BELLUS Health Inc. (BLU)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.81-0.24 (-3.97%)
At close: 04:00PM EST
5.81 0.00 (0.00%)
After hours: 04:00PM EST

BELLUS Health Inc.

275 Armand-Frappier Boulevard
Laval, QC H7V 4A7
450 680 4500

Full-time employees32

Key executives

NameTitlePayExercisedYear born
Mr. Roberto Francesco BelliniPres, CEO & Director433.17kN/A1980
Mr. Ramzi BenamarChief Financial Officer334.24kN/A1973
Dr. Denis GarceauChief Scientific Officer272.46kN/A1957
Mr. Francois Desjardins C.A., CPA, CPA, CASr. VP of Fin.176.85kN/A1963
Dr. Catherine M. BonuccelliChief Medical Officer452.83kN/A1958
Mr. Daniel MatthewsDirector of Investor Relations & CommunicationsN/AN/AN/A
Mr. Tony MatzouranisSr. VP of Bus. Devel.N/AN/A1973
Mr. Sebastien RoyCorp. Sec.N/AN/A1976
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada.

Corporate governance

BELLUS Health Inc.’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 3; Board: 8; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.